ARCT - Arcturus Therapeutics Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

4.91

-0.19 (-3.73%)

At close: 3:52PM EDT

Stock chart is not supported by your current browser

Previous Close	5.10
Open	5.15
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	4.90 - 5.23
52 Week Range	4.78 - 15.19
Volume	17,679
Avg. Volume	55,851

Market Cap	N/A
Beta	2.43
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	13.33

Trade prices are not sourced from all markets

All

News

Press Releases

ACCESSWIRE3 days ago
Blog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosure
Stock Monitor: PLx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd (NASDAQ: ARCT ) ("Arcturus"). ...
GlobeNewswire4 days ago
Arcturus Therapeutics Founder Joseph Payne Dismisses Board’s Baseless Lawsuit as Desperate Entrenchment Tactic
Warns lawsuit is another attempt by Arcturus’ board to distract shareholders from the Company’ s abhorrent governance deficiencies Calls on board to respect the rights of all shareholders and immediately ...
GlobeNewswire7 days ago
Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, initiated a lawsuit in the United States District Court for the Southern District of California on April 19, 2018 against former President and Chief Executive Officer (CEO), Joseph E. Payne, and his associates, including Bradley Sorenson, Peter Farrell and Andrew Sassine (collectively, with other unknown shareholders, the “Payne Group”), for multiple violations of federal disclosure and reporting rules under Section 13(d) of the Exchange Act and Regulation 13D. The lawsuit seeks injunctive relief to compel the Payne Group to comply with Regulation 13D and prevent Payne and the other Defendants from future violations of Section 13(d). The filing also outlines how Payne has illegally and secretly colluded with multiple shareholders to support his vindictive campaign to replace the full Arcturus Board of Directors.
GlobeNewswire14 days ago
Arcturus Therapeutics Founder Joseph Payne Disappointed by Board’s Desperate Attempt to Delay Meeting and Avoid Shareholder Accountability
Change in Arcturus board is needed on an urgent basis to improve the company’ s performance Board’ s decision to indefinitely delay inevitable change is a clear act of entrenchment Overwhelming support ...
GlobeNewswire19 days ago
Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders
Postponement due to Joseph Payne’ s Focus on Advancing His Personal Agenda at the Expense of Arcturus Shareholders. SAN DIEGO, April 08, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, ...
GlobeNewswirelast month
Arcturus Therapeutics Issues Open Letter to Shareholders
Details Former President and CEO Joseph E. Payne’ s Poor Judgment, Failed Leadership and Deceit that Led to His Termination for Cause. Cites Payne’ s Self-Dealing and Blatant Disloyalty to Arcturus, its ...
GlobeNewswirelast month
Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders
Complaint Details Extensive Misconduct by Mr. Payne during Tenure as CEO. Payne’ s Self-Dealing and Inappropriate Business Conflicts of Interest.
GlobeNewswire2 months ago
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors. SAN DIEGO, March 11, 2018-- Arcturus Therapeutics Ltd., an RNA medicines company, today announced that it will ...
GlobeNewswire2 months ago
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach
SAN DIEGO, March 05, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today issued the following statement regarding the previously announced process for members of the Company’ s Board ...
GlobeNewswire2 months ago
Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders
SAN DIEGO, Feb. 26, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that, based on the preliminary vote count provided by its transfer agent following Arcturus’ extraordinary ...
GlobeNewswire2 months ago
Arcturus Therapeutics Comments on Amended 13D Filing
SAN DIEGO, Feb. 16, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today commented on the amended 13 D filing by Joseph E. Payne, who was fired from Arcturus as of February 1, 2018, ...
ACCESSWIRE2 months ago
Wired News – Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of R&D
Stock Monitor: Highwoods Properties Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd. (NASDAQ: ...
GlobeNewswire2 months ago
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
Pad Chivukula Resigns as Chief Scientific Officer and Chief Operating Officer. SAN DIEGO, Feb. 12, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that Dr. Christine ...
GlobeNewswire3 months ago
Arcturus Therapeutics Issues Statement
SAN DIEGO, Feb. 06, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today issued the following statement in response to the 13 D filing issued by Joseph E. Payne:. We are aware of the ...
GlobeNewswire3 months ago
Arcturus Therapeutics Appoints Mark Herbert as Interim President
SAN DIEGO, Feb. 02, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that Mark R. Herbert, Vice President of Business Development and Alliance Management, has been appointed ...
GlobeNewswire3 months ago
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
SAN DIEGO, Jan. 30, 2018-- Arcturus Therapeutics Ltd., or Arcturus, an RNA medicines company, today announced that it will hold an extraordinary general meeting of shareholders on Monday, February 26, ...
Business Wire4 months ago
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. , an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA therapeutics.
Simply Wall St.5 months ago
Should You Buy Alcobra Ltd (ARCT)?
Alcobra Ltd (NASDAQ:ARCT), a pharmaceuticals company based in Israel, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last few months. AsRead More...